![logo](/logos/CPRX.webp)
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
19.6 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Catalyst Pharmaceuticals, Inc. |
Symbool | CPRX |
Munteenheid | USD |
Prijs | 19.6 |
Beurswaarde | 2,326,284,800 |
Dividendpercentage | 0% |
52-weken bereik | 11.55 - 20.87 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Patrick J. McEnany |
Website | https://www.catalystpharma.com |
An error occurred while fetching data.
Over Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)